A new report by the National Pharmacy Association reveals that patients spent over 6 million hours in A&E last year for minor health issues that could have been managed by community pharmacies, highlighting an opportunity to ease pressure on emergency services.
Joseph Najjar and Andrew K. Udit, PhD from the Department of Chemistry at Occidental College enlighten us on the importance of Cytochromes P450 in medicine and industry.
Neil Osheroff from the Vanderbilt University School of Medicine is working to overcome drug resistance and revitalise the use of established targets for antibacterial agents, as we discover here.
Prof Dr Freimut Schliess, Director of Science & Innovation at the Profil Institut für Stoffwechselforschung GmbH, shares a vision for remote decentralised clinical trials.
Dr Frank Wuest, Professor at Department of Oncology - University of Alberta, sheds light on the imaging biomarkers and the Alberta Radiopharmaceutical Collaboration in this special oncology focus.
Here, experts Stephan Pleschka, Oliver Planz and Stephan Ludwig walk us through the constant threat of influenza virus outbreaks and the benefit of enduring research in antiviral drug development.
Here, OilsBySimpson Founder Kevin William Simpson, explains what current research shows about CBD’s effect on epilepsy and its applications as a treatment.
Jay Sibbitts, Shu Jia, Obdulia Covarrubias-Zambrano, Stefan H. Bossmann and Christopher T Culbertson from Kansas State University’s Department of Chemistry walk us through what we need to know about microfluidic devices for detecting pain.
Scientists at TCS designed novel chemical compounds using AI that can inhibit the 3CL protease of SARS-CoV-2, which is responsible for viral replication. Ananth Krishnan, Chief Technology Office, TCS, discusses the research here.
Several drugs used for curing hepatitis C have been identified as potential candidates to treat COVID-19, according to research conducted using the MOGON II supercomputer at Johannes Gutenberg University Mainz.
Liam McGreevy, CEO of Ethnopharm Ltd, explains his thoughts on creating value in today’s maturing cannabis market, including how the firm can help both new and established businesses make sense of this.
